Reata Pharma (RETA) Misses Q4 EPS by 76c, Revenues Miss

Reata Pharma (NASDAQ: RETA) reported Q4 EPS of ($5.91), $0.76 worse than the analyst estimate of ($5.15). Revenue for the quarter came in at $2.67 million versus the consensus estimate of $6.49 million.

“In 2019, we made significant progress toward our goal of becoming a global, fully-integrated biopharmaceutical company,” said Warren Huff, Reata’s Chief Executive Officer and President. “We announced positive, pivotal data from our lead franchises, chronic kidney disease (CKD) and neurology, and are actively preparing for commercial launch in the United States and abroad for bardoxolone methyl (bardoxolone) in CKD caused by Alport syndrome, and omaveloxolone in Friedreich’s ataxia, two severe and life-threatening diseases without approved therapies. We also successfully capitalized the Company to fund the development of our pipeline assets and advance our lead drug candidates and early-stage drug candidates into new indications with high unmet need.”

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49